Dementia of the eye: The role of amyloid beta in retinal degeneration

Eye (Basingstoke)

Volumn 29, Issue 8, 2015, Pages 1013-1026

  Ratnayaka, J A ^a   Serpell, L C ^b   Lotery, A J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY;

AGE; AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CELL FUNCTION; HUMAN; HYPOTHESIS; MICROENVIRONMENT; MOLECULAR DYNAMICS; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PREVALENCE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETINITIS; RISK FACTOR; SIGNAL TRANSDUCTION; AGING; DISEASE COURSE; METABOLISM; PATHOLOGY; QUALITY OF LIFE; RETINA; RETINA DEGENERATION;

AGING; AMYLOID BETA-PEPTIDES; DISEASE PROGRESSION; HUMANS; QUALITY OF LIFE; RETINA; RETINAL DEGENERATION; RISK FACTORS;

EID: 84939199775     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.100     Document Type: Article

References (104)

1. Khandhadia S, Cherry J, Lotery AJ. Age-related macular degeneration. Adv Exp Med Biol 2012; 724: 15-36.
2. Cipriani V, LeungHT, Plagnol V, Bunce C, Khan JC, ShahidH et al. Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXBFKBPL-NOTCH4 region of chromosome 6p21.3. Hum Mol Genet 2012; 21(18): 4138-4150.
3. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G et al. Seven new loci associated with agerelated macular degeneration. Nat Genet 2013; 45(4): 433-2.
4. Lotery A. Progress in understanding and treating agerelated macular degeneration. Eye (Lond) 2008; 22(6): 739-741.
5. Lotery A, Trump D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet 2007; 122(3-4): 219-236.
6. Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 2011; 30(4): 217-238.
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-356.
8. Benilova I, Karran E, De SB. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15(3): 349-357.
9. Gordois A, Cutler H, Pezzullo L, Gordon K, Cruess A, Winyard S et al. An estimation of the worldwide economic and health burden of visual impairment. Glob Public Health 2012; 7(5): 465-481.
10. Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol 2010; 128(6): 750-758.
11. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122(4): 564-572.
12. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99(23): 14682-14687.
13. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134(3): 411-431.
14. Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 2005; 115(10): 2793-2800.
15. Wang J, Zhu C, Xu Y, Liu B, Wang M, Wu K. Development and expression of amyloid-beta peptide 42 in retinal ganglion cells in rats. Anat Rec (Hoboken) 2011; 294(8): 1401-1405.
16. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990; 87(2): 257-263.
17. Shariati SA, De SB. Redundancy and divergence in the amyloid precursor protein family. FEBS Lett 2013; 587(13): 2036-2045.
18. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258(5079): 126-129.
19. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359(6393): 322-325.
20. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-112.
21. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr., Eckman C et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994; 264(5163): 1336-1340.
22. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases betaprotein production. Nature 1992; 360(6405): 672-674.
23. De SB. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010; 90(2): 465-494.
24. Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M et al. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J 2011; 30(11): 2255-2265.
25. Kim W, Hecht MH. Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40. J Biol Chem 2005; 280(41): 35069-35076.
26. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H et al. 3D structure of Alzheimer's amyloid-beta (1-42) fibrils. Proc Natl Acad Sci USA 2005; 102(48): 17342-17347.
27. Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F et al. Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol 2007; 5(11): e290.
28. Ward RV, Jennings KH, Jepras R, Neville W, Owen DE, Hawkins J et al. Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of betaamyloid peptide. Biochem J 2000; 348(Pt 1): 137-144.
29. Jarrett JT, Berger EP, Lansbury PT Jr.. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32(18): 4693-4697.
30. Sabate R, Estelrich J. Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. J Phys Chem B 2005; 109(21): 11027-11032.
31. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA 1997; 94(15): 7942-7947.
32. Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 2011; 7(9): 602-609.
33. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95(11): 6448-6453.
34. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46(6): 860-866.
35. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133(Pt 5): 1328-1341.
36. Williams TL, Day IJ, Serpell LC. The effect of Alzheimer's Abeta aggregation state on the permeation of biomimetic lipid vesicles. Langmuir 2010; 26(22): 17260-17268.
37. Narayan P, Ganzinger KA, McColl J, Weimann L, Meehan S, Qamar S et al. Single molecule characterization of the interactions between amyloid-beta peptides and the membranes of hippocampal cells. J Am Chem Soc 2013; 135 (4): 1491-1498.
38. Chafekar SM, Baas F, Scheper W. Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta 2008; 1782(9): 523-531.
39. Bezprozvanny I. Amyloid goes global. Sci Signal 2009; 2 (63): pe16.
40. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461(7266): 916-922.
41. Selkoe DJ. Amyloid protein and Alzheimer's disease. Sci Am 1991; 265(5): 68-6 78.
42. Williams TL, Serpell LC. Membrane and surface interactions of Alzheimer's Abeta peptide-insights into the mechanism of cytotoxicity. FEBS J 2011; 278(20): 3905-3917.
43. Fandrich M. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J Mol Biol 2012; 421(4-5): 427-440.
44. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999; 158(2): 328-337.
45. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Accumulation of intraneuronal beta-amyloid
46. peptides is associated with early changes in microtubuleassociated protein 2 in neurites and synapses. PLoS One 2013; 8(1): e51965.
47. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27(4): 796-807.
48. Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 1999; 155(1): 23-28.
49. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8(1): 79-84.
50. Liu RQ, Zhou QH, Ji SR, Zhou Q, Feng D, Wu Y et al. Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. J Biol Chem 2010; 285(26): 19986-19996.
51. Soura V, Stewart-Parker M, Williams TL, Ratnayaka A, Atherton J, Gorringe K et al. Visualization of co-localization in Abeta42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. Biochem J 2012; 441(2): 579-590.
52. Wu F, Yao PJ. Clathrin-mediated endocytosis and Alzheimer's disease: an update. Ageing Res Rev 2009; 8(3): 147-149.
53. Song MS, Baker GB, Todd KG, Kar S. Inhibition of betaamyloid1-
54. internalization attenuates neuronal death by stabilizing the endosomal-lysosomal system in rat cortical cultured neurons. Neuroscience 2011; 178: 181-188.
55. Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch Clin Exp Ophthalmol 2009; 247(9): 1213-1221.
56. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99(18): 11830-11835.
57. Prakasam A, Muthuswamy A, Ablonczy Z, Greig NH, Fauq A, Rao KJ et al. Differential accumulation of secreted AbetaPP metabolites in ocular fluids. J Alzheimers Dis 2010; 20(4): 1243-1253.
58. Wang J, Ohno-Matsui K, Morita I. Elevated amyloid beta production in senescent retinal pigment epithelium, a possible mechanism of subretinal deposition of amyloid beta in age-related macular degeneration. Biochem Biophys Res Commun 2012; 423(1): 73-78.
59. AndersonDH, Talaga KC, RivestAJ, Barron E, HagemanGS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 2004; 78(2): 243-256.
60. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359(6393): 325-327.
61. Moghekar A, Rao S, Li M, Ruben D, Mammen A, Tang X et al. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem 2011; 286(18): 15989-15997.
62. Hoh KJ, Lenassi E, Jeffery G. Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. PLoS One 2010; 5(10): e13127.
63. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 2006; 116(2): 378-385.
64. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007; 48(5): 2285-2289.
65. Liu RT, Gao J, Cao S, Sandhu N, Cui JZ, Chou CL et al. Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration. Invest Ophthalmol Vis Sci 2013; 54(3): 2225-2237.
66. Isas JM, Luibl V, Johnson LV, Kayed R, Wetzel R, Glabe CG et al. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 2010; 51(3): 1304-1310.
67. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 2003; 9: 184-190.
68. Kurji KH, Cui JZ, Lin T, Harriman D, Prasad SS, Kojic L et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010; 51(2): 1151-1163.
69. Cao L, Wang H, Wang F, Xu D, Liu F, Liu C. Abeta-induced senescent retinal pigment epithelial cells create a proinflammatory microenvironment in AMD. Invest Ophthalmol Vis Sci 2013; 54(5): 3738-3750.
70. Holtkamp GM, Kijlstra A, Peek R, de Vos AF. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 2001; 20(1): 29-48.
71. Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007; 85(4): 462-472.
72. Liu XC, Liu XF, Jian CX, Li CJ, He SZ. IL-33 is induced by amyloid-beta stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells. Inflammation 2012; 35(2): 776-784.
73. Bruban J, Glotin AL, Dinet V, Chalour N, Sennlaub F, Jonet L et al. Amyloid-beta(1-42) alters structure and function of retinal pigmented epithelial cells. Aging Cell 2009; 8(2): 162-177.
74. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012; 149(4): 847-859.
75. Tsuruma K, Tanaka Y, Shimazawa M, Hara H. Induction of amyloid precursor protein by the neurotoxic peptide, amyloid-beta 25-35, causes retinal ganglion cell death. J Neurochem 2010; 113(6): 1545-1554.
76. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104(33): 13444-13449.
77. Khandhadia S, Cipriani V, Yates JR, Lotery AJ. Age-related macular degeneration and the complement system. Immunobiology 2012; 217(2): 127-146.
78. Anderson DH, RadekeMJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29(2): 95-112.
79. Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998; 188(3): 431-438.
80. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21(3): 383-421.
81. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102(20): 7227-7232.
82. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4(8): 617-629.
83. Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 2004; 14(4): 426-432.
84. Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 2012; 90(4): 299-309.
85. Blasiak J, Glowacki S, Kauppinen A, Kaarniranta K. Mitochondrial and nuclear DNA damage and repair in agerelated macular degeneration. Int J Mol Sci 2013; 14(2): 2996-3010.
86. Cunvong K, Huffmire D, Ethell DW, Cameron DJ. Amyloid-beta increases capillary bed density in the adult zebrafish retina. Invest Ophthalmol Vis Sci 2013; 54(2): 1516-1521.
87. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 2014; 15: 151-171.
88. Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 2011; 6(8): e23789.
89. McKay GJ, Patterson CC, Chakravarthy U, Dasari S, Klaver CC, Vingerling JR et al. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of
90. studies. Hum Mutat 2011; 32(12): 1407-1416.
91. Curcio CA, Johnson M, Rudolf M, Huang JD. The oil spill in ageing Bruch membrane. Br J Ophthalmol 2011; 95(12): 1638-1645.
92. Loane E, McKay GJ, Nolan JM, Beatty S. Apolipoprotein E genotype is associated with macular pigment optical density. Invest Ophthalmol Vis Sci 2010; 51(5): 2636-2643.
93. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90(17): 8098-8102.
94. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3(89): 89ra57.
95. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J 2011; 25(5): 1585-1595.
96. Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, Pronzato MA et al. Cholesterol and Alzheimer's disease: a still poorly understood correlation. IUBMB Life 2012; 64(12): 931-935.
97. Castello MA, Soriano S. Rational heterodoxy: cholesterol reformation of the amyloid doctrine. Ageing Res Rev 2013; 12(1): 282-288.
98. Wang J, Ohno-Matsui K, Morita I. Cholesterol enhances amyloid beta deposition in mouse retina by modulating the activities of Abeta-regulating enzymes in retinal pigment epithelial cells. Biochem Biophys Res Commun 2012; 424(4): 704-709.
99. Dasari B, Prasanthi JR, Marwarha G, Singh BB, Ghribi O. Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina. BMC Ophthalmol 2011; 11: 22.
100. Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW et al. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci USA 2005; 102(33): 11900-11905.
101. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 2011; 108(28): E279-E287.
102. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 2001; 112 (10): 1860-1867.
103. Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D'Antonio F et al. Choroidal thinning as a new finding in Alzheimer's disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis 2014; 40(4): 907-917.
104. Morris KL, Rodger A, Hicks MR, Debulpaep M, Schymkowitz J, Rousseau F et al. Exploring the sequencestructure relationship for amyloid peptides. Biochem J 2013; 450: 275-283.